$ALKS News

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026

Alkermes (ALKS) Holds To Its Narrative, Is The Pullback A Buying Opportunity?

Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target

Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290

Alkermes: The Orexin Upside Is Real, But Takeda And Lilly Stand In The Way (Downgrade)

Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says

RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target

Baird Maintains Outperform on Alkermes, Raises Price Target to $61

How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment

Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Needham Reiterates Buy on Alkermes, Maintains $62 Price Target

Alkermes Shares Topline Results From Phase 1 Proof-of-concept Study Evaluating ALKS 7290 For Attention-deficit Hyperactivity Disorder, Showing Meaningful Improvements In Patients

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors